Rep. Josh Gottheimer Unloads Insmed, Inc. (NASDAQ:INSM) Shares

Representative Josh Gottheimer (Democratic-New Jersey) recently sold shares of Insmed, Inc. (NASDAQ:INSM). In a filing disclosed on July 07th, the Representative disclosed that they had sold between $1,001 and $15,000 in Insmed stock on June 10th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Nintendo (OTCMKTS:NTDOY) on 6/17/2026.
• Sold $1,001 – $15,000 in shares of Agree Realty (NYSE:ADC) on 6/1/2026.
• Sold $1,001 – $15,000 in shares of Novozymes A/S (OTCMKTS:NVZMY) on 6/1/2026.
• Sold $1,001 – $15,000 in shares of Nestle (OTCMKTS:NSRGY) on 6/1/2026.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 6/1/2026.
• Sold $1,001 – $15,000 in shares of Booking (NASDAQ:BKNG) on 6/1/2026.
• Sold $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 5/27/2026.
• Purchased $1,001 – $15,000 in shares of Lumentum (NASDAQ:LITE) on 5/22/2026.
• Sold $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 5/22/2026.
• Purchased $1,001 – $15,000 in shares of Micron Technology (NASDAQ:MU) on 5/21/2026.

Insmed Price Performance

Shares of NASDAQ INSM opened at $115.61 on Monday. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80. Insmed, Inc. has a 12-month low of $90.39 and a 12-month high of $212.75. The firm’s 50-day moving average price is $107.21 and its 200-day moving average price is $138.01. The stock has a market capitalization of $25.06 billion, a price-to-earnings ratio of -20.11 and a beta of 0.78.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The company had revenue of $305.96 million during the quarter, compared to analyst estimates of $300.81 million. During the same quarter last year, the business posted ($1.42) earnings per share. The firm’s revenue was up 229.7% on a year-over-year basis. On average, equities research analysts anticipate that Insmed, Inc. will post -2.55 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on INSM shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Insmed in a report on Tuesday, April 21st. Leerink Partners raised their price target on Insmed from $210.00 to $215.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 24th. Barclays boosted their price objective on shares of Insmed from $231.00 to $237.00 and gave the company an “overweight” rating in a research report on Wednesday, April 1st. Guggenheim reissued a “buy” rating and issued a $207.00 target price on shares of Insmed in a research note on Friday. Finally, HC Wainwright restated a “buy” rating on shares of Insmed in a report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Insmed has an average rating of “Moderate Buy” and a consensus price target of $211.00.

Insider Transactions at Insmed

In related news, COO Roger Adsett sold 2,370 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $242,379.90. Following the transaction, the chief operating officer owned 98,603 shares of the company’s stock, valued at $10,084,128.81. This represents a 2.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Michael Alexander Smith sold 1,806 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $95.82, for a total value of $173,050.92. Following the completion of the transaction, the insider directly owned 37,648 shares in the company, valued at approximately $3,607,431.36. This trade represents a 4.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 65,289 shares of company stock worth $7,334,073 over the last three months. Company insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Norges Bank bought a new stake in Insmed during the 4th quarter valued at about $506,625,000. RTW Investments LP grew its stake in Insmed by 57.0% in the 4th quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company’s stock worth $842,855,000 after acquiring an additional 1,758,321 shares in the last quarter. Orbis Allan Gray Ltd purchased a new position in shares of Insmed during the second quarter worth approximately $153,389,000. State Street Corp increased its position in shares of Insmed by 30.6% during the fourth quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock worth $905,312,000 after acquiring an additional 1,217,390 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Insmed by 5.7% during the fourth quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock valued at $3,668,127,000 after acquiring an additional 1,140,524 shares in the last quarter.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.

Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.

Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.

Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.